Evotec and Claris Ventures streamline access to accelerate programmes from
Claris's portfolio companies into the clinic

EQS-News: Evotec SE / Key word(s): Miscellaneous
Evotec and Claris Ventures streamline access to accelerate programmes from
Claris's portfolio companies into the clinic

06.03.2024 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

  * CLARIS'S PORTFOLIO COMPANIES RECEIVE EASY ACCESS TO EVOTEC'S FULL RANGE
    OF PRE-CLINICAL AND CLINICAL DEVELOPMENT AND MANUFACTURING CAPABILITIES

  * AGREEMENT BUILDS ON SUCCESSFUL COLLABORATION BETWEEN EVOTEC AND CLARIS'S
    PORTFOLIO COMPANY IAMA

Hamburg, Germany, and Turin, Italy, 06 March 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809;
NASDAQ: EVO) and biotech venture capital firm Claris Ventures ("Claris")
today announced an acceleration framework to streamline programmes from
Claris's portfolio companies into the clinic through Evotec's fully
integrated platform.

Claris's portfolio is focused on biotech companies with programmes
approaching clinical trials and currently consists of nine biotech companies
across Italy, Switzerland, and the UK. Claris provides resources,
capabilities, and connections to complete pre-clinical studies and run
first-in-human ("FIH") trials.

Evotec is already supporting Claris's portfolio company IAMA Therapeutics
("IAMA"), a Genoese Biotech company focused on innovative medicines for
brain disorders. Evotec has provided IAMA with pre-clinical services,
including INDiGO, for IAMA's fully owned lead programme IAMA-6, culminating
in a successful Clinical Trial Application ("CTA") in December 2023.

In January 2024, IAMA announced the first dosing in a Phase I first-in-human
study, which is sponsored by IAMA and managed by Evotec. The study will
investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and
food effect of IAMA-6. Evotec also manufactures the drug substance and drug
product at its Campus Levi-Montalcini in Verona, Italy.

Building on this success, the acceleration framework agreement now provides
Claris's other portfolio companies with easy access to Evotec's full range
of integrated services. Evotec will also support the successful progress of
integrated programmes through a governance model.

Dr Matthias Evers, Chief Business Officer of Evotec, commented: "We are
excited to enter this agreement with our partners at Claris. Streamlining
the process to the clinic is one of the major efficiency unlocks of our
fully integrated R&D platform. As Claris's portfolio grows and matures, we
look forward to the opportunity to provide further companies with simplified
access to our full stack of services and to help deliver their potential to
the fullest."

Pietro Puglisi, Managing Partner at Claris, added: "We are pleased to embark
on this strategic partnership with Evotec. The agreement enhances our
ability to expedite the progression of our portfolio companies from
discovery to clinical stages. Evotec's integrated services have proven
instrumental in advancing IAMA Therapeutics' lead programme, IAMA-6, and we
look forward to leveraging their expertise to further accelerate the
development of transformative drug candidates within our expanding
portfolio. This collaboration aligns with Claris's commitment to fostering
innovation and delivering impactful solutions to address unmet medical
needs."


ABOUT CLARIS VENTURES
Claris Ventures SGR is a venture capital firm based in Italy, founded in
2019. Its first fund under management, Claris Biotech I, with EUR85 million
under management, is focused on early-stage investments in high potential
biopharma companies arisen from the Italian R&D ecosystem - both local and
international. The firm identifies and supports innovation in the
pharmaceutical space, investing in new companies with transformational drugs
under development. It aims at the highest impact possible on highly unmet
patients need, building value around strong science. Claris Ventures SGR
pursuit for high potential projects involves every research center, clinical
structure and company in the Italian life sciences network, whether the
founding team is based in Italy or it includes Italian scientists abroad who
have strong links with Italy. For additional information please go to
www.clarisventures.com and follow us on LinkedIn.

ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers
on its mission to discover and develop highly effective therapeutics and
make them available to the patients. The Company's multimodality platform
comprises a unique combination of innovative technologies, data and science
for the discovery, development, and production of first-in-class and
best-in-class pharmaceutical products. Evotec leverages this "Data-driven
R&D Autobahn to Cures" for proprietary projects and within a network of
partners including all Top 20 Pharma and over 800 biotechnology companies,
academic institutions, as well as other healthcare stakeholders. Evotec has
strategic activities in a broad range of currently underserved therapeutic
areas, including e.g. neurology, oncology, as well as metabolic and
infectious diseases. Within these areas of expertise, Evotec aims to create
the world-leading co-owned pipeline for innovative therapeutics and has
to-date established a portfolio of more than 200 proprietary and co-owned
R&D projects from early discovery to clinical development. Evotec operates
globally with more than 5,000 highly qualified people. The Company's 17
sites offer highly synergistic technologies and services and operate as
complementary clusters of excellence. For additional information please go
to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future
events, including the proposed offering and listing of Evotec's securities.
Words such as "anticipate," "believe," "could," "estimate," "expect,"
"intend," "may," "might," "plan," "potential," "should," "target," "would"
and variations of such words and similar expressions are intended to
identify forward-looking statements. Such statements include comments
regarding Evotec's expectations for revenues, Group EBITDA and unpartnered
R&D expenses. These forward-looking statements are based on the information
available to, and the expectations and assumptions deemed reasonable by
Evotec at the time these statements were made. No assurance can be given
that such expectations will prove to have been correct. These statements
involve known and unknown risks and are based upon a number of assumptions
and estimates, which are inherently subject to significant uncertainties and
contingencies, many of which are beyond the control of Evotec. Evotec
expressly disclaims any obligations or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in Evotec's expectations with respect thereto or any
change in events, conditions or circumstances on which any statement is
based.

Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications,
Gabriele.Hansen@evotec.com
Hinnerk Rohwedder, Director of Global Corporate Communications,
Hinnerk.Rohwedder@evotec.com

IR Contact Evotec SE:
Volker Braun, EVP Head of Global Investor Relations & ESG,
Volker.Braun@evotec.com


---------------------------------------------------------------------------

06.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Evotec SE
                   Manfred Eigen Campus / Essener Bogen 7
                   22419 Hamburg
                   Germany
   Phone:          +49 (0)40 560 81-0
   Fax:            +49 (0)40 560 81-222
   E-mail:         info@evotec.com
   Internet:       www.evotec.com
   ISIN:           DE0005664809
   WKN:            566480
   Indices:        MDAX, TecDAX
   Listed:         Regulated Market in Berlin, Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Dusseldorf, Hamburg,
                   Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
   EQS News ID:    1851857

End of News EQS News Service
---------------------------------------------------------------------------

1851857 06.03.2024 CET/CEST